Recombinant Human MTAP His-tag Protein, CF Summary
The specific activity is >650 pmol/min/μg, as measured under the described conditions.
with an N-terminal Met and 6-His tag
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Supplied as a 0.2 μm filtered solution in Tris, NaCl and TCEP.|
|Shipping||The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- Assay Buffer: 50 mM Potassium Phosphate, 1 mM DTT, pH 7.4
- Recombinant Human Methylthioadenosine Phosphorylase (rhMTAP) (Catalog # 10379-MT)
- 5'-Deoxy-5'-Methylthioadenosine (MTA) (Cayman Chemical, Catalog # 15593), 30 mM stock in DMSO
- Xanthine Oxidase (Sigma, Catalog # X2252), 200 U/mL stock in 10 mM Potassium Phosphate, pH 7.4
- UV Plate (Costar, Catalog # 3635)
- Plate Reader (Model: SpectraMax Plus by Molecular Devices) or equivalent
- Dilute rhMTAP to 2 µg/mL in Assay Buffer.
- Prepare Substrate Mixture containing 600 µM MTA and 6 U/mL Xanthine Oxidase in Assay Buffer.
- Load into a plate 50 µL of 2 µg/mL rhMTAP, and start the reaction by adding 50 µL of Substrate Mixture. Include a Substrate Blank containing 50 µL of Assay Buffer and 50 µL of Substrate Mixture.
- Seal the plate and incubate at room temperature for 15 minutes.
- Read plate at 305 nm (absorbance) in kinetic mode for 5 minutes.
- Calculate specific activity:
Specific Activity (pmol/min/µg) =
|Adjusted Vmax* (OD/min) x well volume (L) x 1012 pmol/mol|
ext. coeff** (M-1cm-1) x path corr.*** (cm) x amount of enzyme (µg)
*Adjusted for Substrate Blank
**Using extinction coefficient 15500 M-1cm-1
***Using the path correction 0.32 cm
Note: the output of many spectrophotometers is in mODPer Well:
- rhMTAP: 0.1 µg
- MTA: 300 µM
- Xanthine Oxidase: 3 U/mL
Recombinant Human MTAP His-tag (Catalog # 10379-MT) is measured by its ability to produce adenine through the conversion of 5'methylthioadenine to 5'methylthioribose-1 phosphate.
2 μg/lane of Recombinant Human MTAP His-tag (Catalog # 10379-MT) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 30-32 kDa under reducing conditions.
Methyl-thioadenosine phosphorylase/MTAP is part of the PNP/MTAP phosphorylase family and catalyzes the reversible phosphorylation of S-methyl-5'-thioadenosine (MTA), a major byproduct of polyamine synthesis essential for cell growth and proliferation. MTAP also produces most of the free adenine generated in human cells through a salvage pathway and thus couples the purine salvage pathway with polyamine biosynthesis. MTAP forms an active trimer where each identical 32 kDa monomer contains a separate active site (1). Each active site contains three distinct regions required for base-, methylthioribose-, and sulfate/phosphate-binding (1). MTAP is cytosolic and abundantly expressed in normal cells and tissues (2). In contrast, deficient MTAP expression is observed in many types of tumors including lung, bladder, pancreatic, and endometrial cancer (3) due to hyper-methylation gene suppression (4) or gene deletion (3, 5, 6). MTA accumulation leads to an immunosuppressive tumor microenvironment and apoptotic resistance (7-9) and MTAP directly regulates the level of MTA present. MTAP has been reported as a tumor suppressor (6,10) that may also act in a manner that is independent of enzymatic activity (11) through signaling pathways such as the insulin-like growth factor-1 receptor pathway (12). Potential therapeutic strategies to exploit MTAP deficiency in tumors (13,14) or inhibit MTAP in tumors that express MTAP, such as prostate cancer, are under investigation (15).
- Appleby, T.C. et al. (1999) Structure 7:629.
- Garbers, D.L. (1978) Biochim. Biophys. Acta. 523:82.
- Li, Y. et al. (2019) J. Cancer 10:927.
- Hellerbrand, C. et al. (2006) Carcinogenesis 27:64.
- Cairns, P. et al. (1995) Nat. Genet. 11:210.
- Christopher, S.A. (2002) Cancer Res. 62:6639.
- Kirovski, G. et al. (2011) Am. J. Pathol. 178:1145.
- Czech, B. et al. (2013) PLoS One 8:e80703.
- Henrich, F.C. et al. (2016) Oncoimmunology 5:e1184802.
- Kadariya, Y. et al. (2009) Cancer Res. 69:5961.
- Tang, B. et al. (2014) G3 (Bethesda) 5:35.
- Xu, J. et al. (2019) Signal Transduct. Target Ther. 4:2.
- Bertino, J.R. et al. (2011) Cancer Biol. Ther. 11:627.
- Tang, B. et al. (2018) Cancer Res. 78:4386.
- Bistulfi, G. et al. (2016) Oncotarget 7:14380.
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant Human MTAP His-tag Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human MTAP His-tag Protein, CF and earn rewards!
Have you used Recombinant Human MTAP His-tag Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image